Table 3:

RA disease characteristics by serum urate and gout status at VARA enrollment^*

	Baseline Serum Urate (sUA)				Baseline Gout Status
	sUA ≤ 6.8 mg/dl	sUA > 6.8 to ≤ 8.0 mg/dl	sUA > 8.0 mg/dl	p-value	Non-gout	Gout	p-value
Disease Activity / Severity
Dis. duration, years, mean (SD)	12 (11)	13 (12)	12 (11)	0.253	12 (11)	11 (12)	0.293
Anti-CCP positive, %	77	82	77	0.235	78	72	0.178
Subcutaneous nodules, %	29	36	35	0.063	30	24	0.235
Radiographic changes, %	54	55	54	0.957	54	51	0.515
MD-HAQ, mean (SD)	0.9 (0.6)	0.8 (0.6)	0.9 (0.6)	0.134	0.9 (0.6)	1.0 (0.6)	0.099
ESR, mm/hr, mean (SD)	26 (23)	25 (20)	29 (25)	0.254	26 (23)	27 (23)	0.758
hsCRP, mg/dl, mean (SD)	1.2 (2.0)	1.2 (1.7)	1.1 (1.6)	0.384	1.2 (1.9)	1.5 (2.5)	0.055
DAS28 category, %				0.773			0.777
Remission (< 2.6)	23	24	22		23	24
Low (≥2.6 to ≤3.2)	15	16	13		15	15
Moderate (>3.2 to ≤5.1)	39	41	45		40	43
High (>5.1)	23	19	21		22	17
Treatments*
Methotrexate, %	54	61	51	0.121	54	63	0.126
Leflunomide, %	12	10	6	0.072	12	7	0.191
Sulfasalazine, %	16	11	12	0.111	14	25	0.007
Hydroxychloroquine, %	35	39	36	0.630	36	30	0.291
Prednisone, %	42	46	42	0.549	42	49	0.208
Biologic therapy, %	29	30	37	0.172	29	24	0.313
NSAID, %	36	29	31	0.057	35	22	0.011
Colchicine, %	7	11	15	0.002	6	58	<0.001
Allopurinol, %	7	10	22	<0.001	5	85	<0.001
Febuxostat, %	0.1	0.5	2.5	0.002	0.1	4.7	<0.001
Any urate lowering therapy, %	7	10	23	<0.001	5	85	<0.001

^*Medications reflect baseline use with exception of gout-related medications (colchicine, allopurinol, febuxostat or other urate lowering medications) that reflect ever use during observation; VARA = Veterans Affairs Rheumatoid Arthritis registry; SD = standard deviation; CCP = cyclic citrullinated peptide; MD-HAQ = Multidimensional Health Assessment Questionnaire; ESR = erythrocyte sedimentation rate; hsCRP = high sensitivity C-reactive protein; DAS28 = 28-joint Disease Activity Score; NSAID = non-steroidal anti-inflammatory drug